Genmab — Juli 2018
-
Umiddelbart er der 4.500 nye patienter om året i USA med sygdommen. http://amyloidosis.org/facts/al/
-
"
In the United States, AL amyloidosis is the most common type, with approximately 4,500 new cases diagnosed every year. It usually affects people from ages 50-80, although there are a few cases of people being diagnosed as early as their late 20s. About two-thirds of the patients are male." -
Hvis vi antager 20.000 WW til 1,5mill.kr, så bliver det 30mia kr. eller 4.5bn$, hvoraf 60% vel er maintenance, som så skal have behandling videre med Dara, så når vi vel op på cirka 6bn$, altså 6-dobbelt BB og royalties på ca. 1bn$, noget jeg regner forkert?
-
En eventuel udmelding omkring Orphan designation skal vel komme fra Janssen?
-
Our retrospective
series of 20 consecutive relapsed AL patients treated with
DARA monotherapy confirms its efficacy and tolerability in
previously treated AL. It is apparent that the single agent activity
of DARA in relapsed AL exceeds that seen in relapsed myeloma
https://sci-hub.mu/10.1111/bjh.15455 -
"Based on our initial experience and that of others, monoclonal antibody therapy targeting CD38 seems likely to herald a promising era in AL amyloidosis therapy."
-
tak for link doc!

-
Stockbull...Orphan designation sikrer en hurtig adgang til markedet. AL Amyloidosis er en sygdom som man ikke rigtigt har noget at skyde med i forvejen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind